Literature DB >> 16629073

Retreatment of LASIK.

Namrata Sharma1, Ramamurthy Balasubramanya, Rajesh Sinha, Jeewan S Titiyal, Rasik B Vajpayee.   

Abstract

PURPOSE: To review the indications, techniques, and results of retreatment LASIK.
METHODS: Review of the literature and the authors' experience.
RESULTS: Patient selection is the key to successful LASIK enhancement. The enhancement procedure should generally be undertaken 3 months after the initial LASIK procedure. Relifting of the flap may be done easily within 1 year of previous LASIK surgery. A new LASIK flap is required in cases with previously complicated LASIK. LASIK retreatment by lifting the flap is an effective and safe procedure. Overall improvement is seen in uncorrected visual acuity (> or = 20/20 and > or = 20/40) and postoperative spherical equivalent refraction within +/- 0.5 D and +/- 1.0 D.
CONCLUSIONS: LASIK retreatment is an effective modality to treat regressions and residual refractive errors.

Entities:  

Mesh:

Year:  2006        PMID: 16629073     DOI: 10.3928/1081-597X-20060401-17

Source DB:  PubMed          Journal:  J Refract Surg        ISSN: 1081-597X            Impact factor:   3.573


  3 in total

1.  Femtosecond lenticule extraction performed on a wrong meridian and effectively reversed by excimer laser ablation.

Authors:  Alper Agca; Yusuf Yildirim; Burçin Kepez Yildiz; Dilek Yasa; Ali Demircan; Ahmet Demirok
Journal:  Lasers Med Sci       Date:  2017-11-13       Impact factor: 3.161

2.  Laser-Assisted In Situ Keratomileusis (LASIK) Enhancement for Residual Refractive Error after Primary LASIK.

Authors:  Majid Moshirfar; Noor F Basharat; Nour Bundogji; Emilie L Ungricht; Ines M Darquea; Matthew E Conley; Yasmyne C Ronquillo; Phillip C Hoopes
Journal:  J Clin Med       Date:  2022-08-18       Impact factor: 4.964

3.  Enhancement of femtosecond lenticule extraction for visual symptomatic eye after myopia correction.

Authors:  Jing Zhao; Peijun Yao; Zhi Chen; Meiyan Li; Yang Shen; Huamao Miao; Xingtao Zhou
Journal:  BMC Ophthalmol       Date:  2014-05-18       Impact factor: 2.209

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.